Literature DB >> 12603395

Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable?

A Sciarra1, G Mariotti, V Gentile, G Voria, A Pastore, S Monti, F Di Silverio.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12603395     DOI： 10.1046/j.1464-410x.2003.03066.x

Source DB:  PubMed          Journal:  BJU Int        ISSN： 1464-4096            Impact factor:   5.588


× No keyword cloud information.
  10 in total

1.  [Neuroendocrine differentiation in prostate cancer: an unrecognized and therapy resistant phenotype].

Authors:  H Bonkhoff; T Fixemer
Journal:  Pathologe       Date:  2005-11       Impact factor: 1.011

2.  Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer.

Authors:  S S Jeetle; G Fisher; Z H Yang; E Stankiewicz; H Møller; C S Cooper; J Cuzick; D M Berney
Journal:  Virchows Arch       Date:  2012-07-06       Impact factor: 4.064

3.  Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism.

Authors:  Norm D Smith; Frank Thilo Schulze-Hoepfner; Dorina Veliceasa; Stephanie Filleur; Sarah Shareef; Lijun Huang; Xue-Mei Huang; Olga V Volpert
Journal:  J Urol       Date:  2008-04-23       Impact factor: 7.450

Review 4.  [Neuroendocrine differentiation in prostate cancer. An unrecognized and therapy-resistant phenotype].

Authors:  H Bonkhoff; T Fixemer
Journal:  Urologe A       Date:  2004-07       Impact factor: 0.639

5.  Wnt/β-catenin activation promotes prostate tumor progression in a mouse model.

Authors:  X Yu; Y Wang; D J DeGraff; M L Wills; R J Matusik
Journal:  Oncogene       Date:  2010-12-13       Impact factor: 9.867

6.  Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.

Authors:  Helmut Bonkhoff
Journal:  Prostate Cancer       Date:  2011-09-08

Review 7.  Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response.

Authors:  Ewa Wojcik; Jan Kanty Kulpa
Journal:  Lung Cancer (Auckl)       Date:  2017-11-28

8.  Prostate cancer susceptibility gene HIST1H1A is a modulator of androgen receptor signaling and epithelial to mesenchymal transition.

Authors:  Kendra A Williams; Minnkyong Lee; Jean M Winter; Derek E Gildea; Carla Calagua; Natasha L Curry; Jens Lichtenberg; Huihui Ye; Nigel P S Crawford
Journal:  Oncotarget       Date:  2018-06-19

9.  Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer.

Authors:  Xiang Xu; Yu-Hua Huang; Yan-Jing Li; Alexa Cohen; Zhen Li; Jill Squires; Wei Zhang; Xu-Feng Chen; Min Zhang; Jiao-Ti Huang
Journal:  Asian J Androl       Date:  2017 Nov-Dec       Impact factor: 3.285

10.  Small-cell prostate carcinoma: A retrospective analysis of five newly reported cases.

Authors:  Kyle R Brownback; Joseph Renzulli; Ronald Delellis; James R Myers
Journal:  Indian J Urol       Date:  2009-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.